Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment

Clinical trial NCT04541017 · TERMINATED

Trial details

NCT number: NCT04541017
Sponsor: National Cancer Institute (NCI)
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Mycosis Fungoides Recurrent Mycosis Fungoides Recurrent Mycosis Fungoides and Sezary Syndrome Recurrent Sezary Syndrome Refractory Mycosis Fungoides Refractory Mycosis Fungoides and Sezary Syndrome Refractory Sezary Syndrome Sezary Syndrome Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8 Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8 Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8 Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8

Start date: 2021-04-06
Primary completion: 2024-10-24
Enrollment: 8

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.